SANUWAVE Health, Inc. reported significant financial improvements in its latest quarterly filing, with revenues for the three months ended September 30, 2025, reaching $11.5 million, a 22% increase from $9.4 million in the same period last year. For the nine months ended September 30, 2025, total revenue was $31.0 million, reflecting a 39% increase compared to $22.3 million for the same period in 2024. The company achieved a net income of $10.3 million for the third quarter, a substantial turnaround from a net loss of $20.7 million in the prior year. This positive shift was attributed to a favorable change in the fair value of derivative liabilities and a one-time gain from a patent sale.
The company’s operational metrics also showed promising growth, particularly in the sales of its UltraMIST® products. The quantity of UltraMIST® disposables sold increased by 23% in the third quarter, while system sales rose by 25%. The average selling price of disposables increased by 3%, contributing to a gross margin of 78% for the quarter, up from 76% in the previous year. However, operating income for the quarter was $1.5 million, down from $2.0 million in the same period last year, primarily due to increased stock-based compensation expenses.
In terms of strategic developments, SANUWAVE executed a comprehensive debt refinancing in September 2025, which included a $23 million secured term loan and a $5 million revolving credit facility. This refinancing extended the maturity of the company’s principal debt obligations and provided additional liquidity to support ongoing operations. The company also reported a significant reduction in total liabilities, which decreased from $42.8 million at the end of 2024 to $38.5 million by September 30, 2025. The successful refinancing and operational improvements have alleviated previous concerns regarding the company's ability to continue as a going concern.
The company’s workforce has also expanded, with an increase in employee headcount contributing to higher general and administrative expenses, which rose to $4.8 million for the third quarter, up from $2.5 million in the same period last year. This increase was driven by non-cash stock-based compensation and higher headcount-related costs. Despite these rising expenses, SANUWAVE's management remains optimistic about the company's financial outlook, citing improved operational efficiency and revenue growth as key factors in their strategy moving forward.
Looking ahead, SANUWAVE Health, Inc. is focused on maintaining its operational momentum and improving its financial position. The management team is committed to monitoring liquidity and compliance with debt covenants while exploring opportunities to enhance the capital structure. The company believes that the steps taken to date, including the successful refinancing and operational improvements, position it well for future growth and stability.
About SANUWAVE Health, Inc.
Sanuwave Health, Inc. develops noninvasive medical devices using ultrasound and shockwave technologies for wound healing and regenerative medicine. Its flagship products, UltraMIST and PACE systems, promote tissue repair, reduce healing times, and improve patient outcomes across acute and chronic wounds. Serving healthcare providers in the U.S. and abroad, the company leverages proprietary technology, FDA clearances, and a patent portfolio to deliver user-friendly, cost-effective solutions in the wound care market.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.